ArticleCancer reports (Hoboken, N.J.)2026
Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAdvanced-stage ovarian cancers exhibit significant variability in responses to standard chemotherapy ranging from platinum-refractory to platinum-sensitive cancers. While genomic testing reveals tissue heterogeneity, it rarely provides actionable data for guiding therapy.
aimsTo evaluate the heterogeneity of ex vivo drug responses in primary ovarian cancer tissues using a functional profiling platform, and to assess the platform's potential for guiding personalized therapy selection within current clinical practice. METHODS AND
resultsA functional profiling platform that creates 3D microtumors from fresh biopsies was used to enable ex vivo assessment of drug efficacy in a physiologically relevant model. Interpatient heterogeneity was quantified as the statistical variability of the EC
conclusionThese findings align with the clinically observed variability in patient responses, highlighting the platform's potential to optimize therapy selection and support patient-centric care within the standard of care for ovarian cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.